HCW Biologics Inc.

HCWBSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1828673

Concept	FY2024	FY2023	FY2022	FY2021
Revenues	—	—	—	$4.1M
Cost of Revenue	$2.3M	$4.1M	$0.00	—
Gross Profit	$560.4K	$2.6M	$0.00	—
Research and Development Expense	$7.7M	$9.3M	$8.2M	$7.3M
Operating Expenses	$26.3M	$17.7M	$13.4M	$9.9M
Operating Income (Loss)	-$25.7M	-$15.1M	-$13.4M	-$5.8M
Interest Expense	$283.0K	$126.7K	$0.00	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$25.0M	-$14.9M	-$12.9M	-$5.8M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$25.0M	-$14.9M

Concept	FY2024	FY2023	FY2022	FY2021
Assets	$28.5M	$46.8M	$53.5M	$15.4M
Assets, Current	$6.4M	$34.1M	$40.5M	$12.1M
Cash and Cash Equivalents, at Carrying Value	$3.6M	$22.3M	$11.7M	$7.4M
Liabilities	$15.1M	$9.4M	$2.3M	—
Liabilities, Current	$8.7M	$3.0M	$2.3M	$1.0M
Long-term Debt	$6.3M	$6.4M	$0.00	—
Accounts Payable, Current	$6.2M	$1.2M	$223.7K	$155.3K
Stockholders' Equity Attributable to Parent	$37.4M	$51.2M	-$16.7M	-$9.7M
Weighted Average Number of Shares Outstanding, Basic

Concept	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$22.5M	-$10.4M	-$11.0M	-$10.4M
Net Cash Provided by (Used in) Investing Activities	$3.8M	$14.7M	-$35.0M	-$186.7K
Net Cash Provided by (Used in) Financing Activities	-$14.5K	$6.3M	$49.3M	$11.7M
Payments to Acquire Property, Plant, and Equipment	$6.2M	$10.3M	$47.3K	$186.7K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)